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Patient Perceptions of Using Clinical Decision Support
for Cancer Screening and Prevention: “I wouldn’t have
thought about getting screened without it.”
Daniel M. Saman, DrPH, MPH,1 Melissa L. Harry, PhD, MSW,2 Laura A. Freitag, BA,2 Clayton I.
Allen, BS,2 Patrick J. O’Connor, MD, MA, MPH,3 JoAnn M. Sperl-Hillen, MD,3 Joseph A. Bianco, MD,4
Anjali R. Truitt, PhD, MPH,3 Heidi L. Ekstrom, MA,3 Thomas E. Elliott, MD3
1
3
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Purpose	We sought to gain an understanding of cancer prevention and screening perspectives among patients
exposed to a clinical decision support (CDS) tool because they were due or overdue for certain
cancer screenings or prevention.
Methods	Semi-structured qualitative interviews were conducted with 37 adult patients due or overdue for cancer
prevention services in 10 primary care clinics within the same health system. Data were thematically
segmented and coded using qualitative content analysis.
Results

 e identified three themes: 1) The CDS tool had more strengths than weaknesses, with areas for
W
improvement; 2) Many facilitators and barriers to cancer prevention and screening exist; and 3)
Discussions and decision-making varied by type of cancer prevention and screening. Almost all
participants made positive comments regarding the CDS. Some participants learned new information,
reporting the CDS helped them make a decision they otherwise would not have made. Participants
who used the tool with their provider had higher self-reported rates of deciding to be screened than
those who did not.

Conclusions	Learning about patients’ perceptions of a CDS tool may increase understanding of how patient-tailored
CDS impacts cancer screening and prevention rates. Participants found a personalized CDS tool for
cancer screening and prevention in primary care useful and a welcome addition to their visit. However,
many providers were not using the tool with eligible patients. (J Patient Cent Res Rev. 2021;8:297-306.)
Keywords	
cancer screening; cancer prevention; clinical decision support; primary care; qualitative research;
decision-making

C

ancer is the second most common cause of death
in the United States1 and one of the costliest
diseases.2,3 Recommendations exist for cancer
prevention and screening based on a body of published
efficacy research, including breast, colorectal, lung, and
cervical and other human papillomavirus (HPV)-linked
cancers.4-10 However, for a number of reasons, patients
may be unaware of or not follow recommendations. Some
patients view cancer screenings as a moral obligation,
a habit, or a tradition.11 Others cite fear of diagnosis,
wasted time and effort, false-positives, practical and
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financial barriers, and lack of understanding as reasons
for avoiding screenings.12 Research suggests that shared
decision-making (SDM) between patients and providers
assists patients with making a decision regarding cancer
prevention and adhering to a cancer screening plan.13,14
While providers may perceive the time required to review
decision aids as a barrier to use,15,16 research has shown
the increased time is marginal.16,17 Expending a little
more time employing SDM during the decision-making
process may improve quality of care.15,16 Furthermore,
innovative tools like algorithm-based clinical decision
support (CDS) may improve the SDM process for patients
and providers.17,18
CDS tools are programmed into electronic health
records, prompting providers when patients are due
and providing recommendations tailored to individual
patients.18-23 CDS can include decision aids — patient-
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focused materials that research has shown can assist
patients with making a decision regarding care that,
while recommended, carries both risks and benefits that
must be weighed for each individual.17,18,21,24 Specifically,
when providers use tools like decision aids, patients
are more likely to make an informed decision based
on credible information with a realistic assessment
of associated risks.16 Research has demonstrated that
provider encouragement to get screened is frequently a
facilitator for patients.25,26
As noted in previous work,22 primary care providers
(PCPs) frequently neglect to engage patients in cancer
screening decision-making processes.27-30 Even with
CDS in place and widespread knowledge on the
importance of SDM in improving patient health, PCPs
have the burdensome task of balancing multiple patient
needs within relatively short visits, including ensuring
patients are up to date on cancer screenings.19,31,32
Consequently, some PCPs may not be utilizing SDM,
decision aids, or CDS as expected due to factors like
time constraints; thus, it can be difficult to assess the
value of SDM in clinical practice.33-35
To address this gap in patient care, an algorithm-based
CDS tool supported by the Chronic Care Model36 was
developed by the study team.21-23,31,37 This point-of-care,
web-based CDS is linked to the electronic health record
for use in health systems and uses algorithms to identify
evidence-based prevention options that address unmet
cancer prevention and screening needs, in addition to
unmet cardiovascular needs among diabetic patients and
those with high, reversible cardiovascular risk.38,39 The
CDS targets primary cancer prevention indicators (body
mass index of >25, HPV vaccination status, tobacco use),
which focus on keeping cancer from originating, and
secondary cancer prevention, which aims to discover
and manage the disease through routine breast, cervical,
colorectal, and lung screening.40 The CDS tool also
provides an efficient workflow for ordering recommended
screening tests, medications, and referrals.
Objective and Guiding Research Questions

Patient experiences are a valuable component within CDSbased studies. However, little research of interviewed
patients who were exposed to a personalized CDS tool
with cancer screening recommendations immediately
following a PCP visit is available. Describing patient
experiences with CDS may help with PCP adoption of
these tools, if patients find value in them. We conducted
patient interviews as part of a clinic-cluster-randomized
controlled trial on the CDS to understand how patients
perceive and make cancer prevention and screening
decisions based on exposure to a personalized CDS

298 JPCRR • Volume 8, Issue 4 • Fall 2021

tool. Our guiding research questions were 1) How do
patients perceive CDS use, recommendations, layout,
and content? 2) What are barriers and facilitators to act
on personalized cancer recommendations from a patient
perspective? and 3) What are patients’ perceptions of the
value of PCPs in the decision-making process?

METHODS

Setting and Participants

The purposive sample in this study included 37
adult (≥20 years of age) patients who, based on
recommendations,4-10 were due or overdue for cancer
screening (breast, cervical, colorectal, lung) and/or
prevention (HPV vaccination, tobacco use, obesity
status) and interested in participating in an interview at
their office visit (for any reason). Visits took place in 10
primary care clinics that are part of an integrated health
system serving a generally rural population, with study
clinic locations in northern Minnesota, eastern North
Dakota, and northwestern Wisconsin.
Qualitative semi-structured interviews were conducted
within clinics in 2 intervention arms of a 3-arm (usual
care, cancer prevention CDS, cancer prevention CDS
plus SDM tools) clinic-randomized trial conducted at
the health system.21,23,31 In the CDS-only intervention
arm, eligible patients could receive a CDS paper handout
noting if they were due or overdue for cancer prevention
and screening, along with cardiovascular risk items
related to another randomized controlled trial.21-23,31
In the CDS plus SDM arm, eligible patients could
receive both the CDS and patient-forward SDM tools
for breast, colorectal, or lung cancer screening or for
HPV vaccination.21,23,31 The CDS also was available to
PCPs electronically in both study arms, with SDM tools
available to only PCPs in the CDS plus SDM arm.21,23,31
The study team created the SDM tools based on existing
literature, expert opinion, and pilot testing.21,23,31
Trial follow-up ended October 31, 2020. Intervention
clinics were encouraged to achieve an 80% CDS print
rate among eligible patients. Rooming staff handed
patients a personally tailored patient printout (Online
Supplemental Figure S1) and placed a more detailed PCP
version (Online Supplemental Figure S2) on the exam
room door.21,23,31
Data Collection

This study was approved by Essentia Health’s institutional
review board. The semi-structured interview guide and
example probing questions are presented in Online
Appendix A. Demographics were collected using a form
that participants completed after the interview (Online
Appendix B). Screening history data were captured by
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study team members reviewing participants’ CDS for
cancer prevention and screening recommendations.
In person, digitally recorded interviews were conducted
from August 14, 2019, to January 22, 2020, by 3 team
members (site principal investigator and site project
managers) working together in dyads in which one team
member led the interview and the other assisted with
probing questions. Patients were recruited through an
informational flyer distributed by clinic rooming staff
during the patient’s appointment at each respective clinic.
The flyer provided study information and the location of
the interview in the clinic. The research team determined
eligibility by reviewing patients’ CDS printouts.
For eligible patients, a semi-structured interview was
conducted with the patient directly after the completion
of their medical appointment. Verbal consent was
established at the beginning of the interview and
reiterated during the interview. Written documentation
of informed consent for participants was waived by
the Essentia Health institutional review board as the
information collected was not considered sensitive.
Participants were given a $20 Visa gift card as a
participation incentive. Interviews were conducted in
an iterative process along with qualitative coding until
thematic data saturation was reached.
Data Analysis

Digitally recorded interviews were professionally
transcribed, error-checked by study team members,
de-identified, and thematically segmented for analysis
in HyperRESEARCH software (version 4.5.0,
Researchware, Inc.).41,42 Throughout data collection,
our methodological approach included qualitative
content analysis and open coding to iteratively develop
and apply a coding frame by 2 site project managers,
with an investigator providing training on qualitative
data analysis, assisting with coding frame development,
adjudicating coding differences,42 and reporting
results. We used a consensus approach wherein we
discussed any disagreements on coding until we
reached consensus, resulting in 100% agreement on
coded segments.

RESULTS

All 37 participants described receiving the CDS printout
from the rooming nurse or assistant, which was the
recommended workflow. Only one individual did not
review the CDS printout during their clinic visit; 10
participants received both patient and provider versions,
while 27 received the patient version of the CDS. Table 1
presents demographics, visit characteristics, and cancer
prevention and screening CDS recommendations for
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Table 1. Descriptive Characteristics of Qualitative
Interview Participants (n=37) in 10 Study Clinics,
August 14, 2019–January 22, 2020
Descriptive characteristic

n (%)

Female sex
Race
   African American
White
   American Indian

27 (73)
1 (3)
34 (92)
2 (5)

Educational level
   High school graduate or GED
Some college or 2-year degree
4-year college graduate
More than 4-year college degree

11 (30)
14 (38)
5 (14)
5 (14)

Reason for clinic visit
   Annual exam visit
   Non-annual exam visit

7 (19)
30 (81)

Patients identified by CDS, of those eligible
   Breast cancer screeninga
Cervical cancer screeningb
Colorectal cancer screeningc
   HPV vaccined
Lung cancer screeninge

13 of 18 (72)
14 of 22 (64)
15 of 26 (58)
4 of 5 (80)
12 of 23 (52)

Note: Recommendations were guided by the U.S.
Preventive Services Task Force and others.4-10
Breast cancer screening eligibility includes women age
50–75 at average risk or women age 35–49 with a 5-year
estimated risk of >2% or lifetime estimated risk of >16.8%,
per the Breast Cancer Risk Assessment Tool.
a

Cervical cancer screening eligibility includes women 21–65
years old.
b

Colorectal cancer screening eligibility includes patients age
18–75 at high risk, age 50–75 not at high risk, or age 40–75
with documented family history or polyps.
c

d

HPV vaccine eligibility includes patients 18–26 years old.

Lung cancer screening eligibility includes patients 55–75
years old.
e

CDS, clinical decision support; HPV, human papillomavirus.

the 37 study participants. Most participants identified
as female (73%), White (92%), and had at least a high
school education (100%). Median age of the study
cohort was 57 years (range: 20–73; mean: 50.8; standard
deviation: 16.2). Participants’ overdue cancer prevention
and screening areas are shown in Table 1.
Three overarching themes emerged from qualitative
coding: strengths outweighed weaknesses in participants’
perceptions of CDS content; many facilitators and barriers
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to cancer prevention and screening exist; and cancer
prevention and screening discussions and decisionmaking vary by type.
Strengths of CDS Content and Opportunities for
Improvement

Most participants described numerous CDS content
strengths (Table 2). For example, participants liked
the CDS information related to cancer screening and
prevention, finding it to be easy to understand: “It’s
straightforward, easy to read. And I’m actually glad I
got it [the CDS] because I wouldn’t have thought about
going in for screening without it.” Participants also

reported liking how the CDS aided PCPs and patients in
discussing cancer prevention and screening: “It’s a good
way to open a door to talk to young people my age, men
and women, about getting screened for cancer.”
Many participants described learning new details related
to cancer prevention and screening from the CDS.
Some participants described already being aware of the
information presented on the CDS: “I kind of had an idea
that I was at risk for a few things.” However, participants
still found value in the CDS: “It’s nothing that I didn’t
know, but it’s nice to have it. Like, I can hang this on
my fridge and say, ‘Hey, I have to remember to do this,’

Table 2. Clinical Decision Support (CDS) Strengths and Weaknesses Reported by Interviewees (n=37)
Theme

n

CDS strengths

36

Patient liked information presented
Easy to understand
Helps manage health priorities

27
9
8

   Prioritizes patient concerns
Information relevant to patient

6
6

Learned new information from the CDS

21

Learned due for cancer screening or prevention

12

Learned other information

5

   Gained new information about cancer prevention options 5
Liked the CDS generally

19

Liked the look/format

13

Good reminder

11

Identified areas to discuss with provider

4

CDS weaknesses

14

Too little information

6

Patient did not understand purpose

6

Cancer priority confusing

1

Recommendations are not reliable if the electronic
health record is not up to date

1

Quotations

It’s easy to understand what you need.
I like that it tells me the things I should do for health care and
stuff; weight, cancer prevention, and everything like that.
I like that it shows me exactly what my priorities should be.
It’s very informative because it tells you all about you.
I had never thought about a lung cancer screening. No.
Never thought about that until today.
It was a little eye-opening, seeing my lifetime danger for a
stroke or slash heart attack, the risk there.
I didn't know a lot of this, about what you can do to prevent
it, stuff like that.
No judgment and I appreciate that because I know I need
to quit [smoking] …That means a lot to me.
I like how [CDS] says, “Priority one, priority two.” It spells
out the priorities. It’s nice to see in writing what you need
to be aware of for your health.
I like that it’s a reminder for when I’m due for stuff because
I thought that I was due for a screening next year. So it
reminded me that I was due.
I was pleased with this. It did bring up more discussions
with my doctor.
[provider version] has a lot more. Yeah, the patient should
have the same amount of info.
I didn’t really know what it was, so I figured my doctor
would tell me.
I glanced and I just saw priority one cancer prevention. I
wasn’t sure what it was.
Some of the information is really incomplete because you
guys don’t have the records from my previous health care
provider.

Note: Interviewees could be included under more than one subtheme.
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instead of trying [to] remember to, ‘Oh, yeah, I’ve got
to schedule that.’” Many participants reported liking
the CDS generally: “It seemed like a great form just to
identify potential issues and highlight them.”

that may need screening. Having a negative experience
with past cancer screening or HPV vaccination was
mentioned as a barrier. Additional patient-level barriers
are noted in Table 3.

The majority of participants could not identify any specific
weaknesses of the CDS content for patients (including
1 individual who did not report any CDS content
strengths). Of those who noted aspects of the CDS that
could be perceived as weaknesses, some were confused
by an aspect of the CDS, such as the caution signs. Some
participants also thought that the CDS could present more
personalized content for patients and required accurate
electronic health record data, suggesting areas for CDS
improvements (Table 2).

Regarding CDS-level barriers to cancer prevention and
screening, some participants said their PCP did not use
the CDS tool during their visit (Table 3). In some cases,
this may be due to a PCP’s lack of familiarity with the
tool; however, other PCPs aware of the CDS chose not
to use it in the visit. In other cases, PCPs covered items
on the CDS without using the tool or instead focused on
the reason for the participant’s visit: “She was too busy.”

Facilitators and Barriers to Cancer Prevention and
Screening at Patient and CDS Levels

Table 4 shows how many of each cancer prevention
or screening recommendation were included on the
CDS printouts for study participants, whether the
recommendation was discussed at the visit, and the
decisions made regarding each recommendation. Seven
(19%) participants did not discuss any cancer screening
or prevention CDS areas with their PCP during their
visit (data not shown in Table 4), in some cases because
it fell outside the reason for the visit: “No. It [cancer
prevention and screening] was unimportant. I’m pretty
sick.” Also, while most of those with cancer prevention
and screening CDS recommendations discussed those
recommendations with their PCP, just 1 of 12 (8%)
candidates eligible for lung cancer screening reported
discussing this option with their PCP.

Participants reported a number of facilitators and barriers
to cancer prevention and screening (Table 3). At the
patient level, personal preferences were a key facilitator
for most participants. For example, many participants
described wanting to discuss cancer prevention with
their PCP. Some talked about the importance of cancer
prevention and screening, including both generally and
personally: “There are some tests I don’t like doing, but
I do them because it’s the best for my health [laughter]
… Do I like to do [a colonoscopy]? No, but should
everybody do it? Yes.”
Regarding CDS-level facilitators, some participants
reported that the CDS assisted them with deciding on
cancer prevention and screening as well as prompted
discussions between participants and their PCPs, with
some participants noting that the CDS provided a
guideline to frame that discussion. The CDS appeared to
facilitate discussion of cancer prevention and screening:
Interviewer: “So, I assume cancer prevention wasn’t
part of your visit today. But did you end up talking
about cancer prevention?”
Participant: “Yeah. We did, actually. We went through
[the CDS]… ‘Cancer screening due.’”
However, just 17 (46%) participants reported reviewing
the CDS with their PCP.
Many participants noted potential patient-level barriers
to cancer screening and prevention (Table 3). Some
reported not wanting to talk about cancer prevention and
screening: “No, because I got enough going on today.”
Some participants were simply not concerned about their
personal risk, either with or without a family history of
cancer. This suggests that PCPs may not be adequately
conveying the risks for common cancers to patients
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Cancer Prevention and Screening Discussions
and Decision-Making May Vary by Type

Since only HPV vaccinations and Pap tests were able to be
performed within the visit, other screenings needed to be
scheduled for the majority of participants (Table 4). Some
individuals chose to schedule screenings or have a Pap
test or HPV vaccination in the office that day. However,
aside from cervical cancer screenings, most participants
did not decide on screening or prevention options that day.
Two individuals were against cancer screening generally,
while 2 other individuals declined the HPV vaccine and
1 reported stopping the series: “Well, I had it done. And
then because of the [allergic] reaction, I didn’t go through
with it anymore.” Yet, of the 4 participants who reported
negative experience with past cancer screening or HPV
vaccination, 3 decided to schedule a screening or had a
Pap performed the day of interviews.
Some participants expressed conflicted feelings regarding
getting screened, which may factor into whether or not
scheduled screening will be successfully completed in the
future: “[The PCP] told me about [the low-dose CT scan],
and I said, ‘Yeah, let’s do it,’ because I was a smoker for all
them years. But it’s like, do I want to know?”
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Table 3. Cancer Prevention and Screening Facilitators and Barriers Described by Interviewees (n=37)
Themes

n

Facilitators

29

Patient level
   Wanted to talk about cancer prevention
   Personal importance of cancer prevention

28
21
13

   General importance of cancer prevention

5

Comfortable discussing cancer prevention

13

Concerned about weight

2

CDS level

21

   PCP used the CDS during the visit with the patient

17

Helped patients decide

8

   Prompted patient/PCP cancer prevention discussion

8

   Provided discussion guidelines

4

   Physical printout made problems real for patients

2

Barriers

25

Patient level
   Did not want to talk about cancer prevention

18
12

   Not concerned about cancer prevention or risk

5

   Negative prior experience with screening

4

Deferred decision on cancer prevention and screening

4

   Not ready to quit smoking

3

   Not willing to address weight

2

Misconception about cancer screening

CDS level
   PCP did not use CDS with the patient during the visit

1

8

Quotations

It’s a good thing to discuss.
I find that very actually interesting because it [cancer] is
a topic I was talking to the doctors before she had even
handed me this [the CDS]. So it was dead-on.
I think it’s great that you’re coming up with more programs
to help people to be more aware [of cancer]. I think you’ll
help people greatly and save a lot of lives.
I think it should be able to be discussed openly and freely
and without bias because, I mean, it’s cancer. Anyone can
get it.
It just motivates me to do better for myself in regards to
watching what I eat.
We looked at it together … and he says, “Yes. Your last
one was a long time ago.” He said, “so we better schedule
you another one.”
It did make me decide, but it also gave me the opportunity
to put it on my terms.
Interviewer: Would you have [discussed cancer prevention]
otherwise if you didn't have that form? Subject: Not today.
It would have been one of those things I would have
forgotten about.
It kind of gave a little bit of a guideline. We had a lot to talk
about. So yeah, it was … nice to have on the way out.
That’s why I hate going to the doctor … and then you get
the paper that you basically, you know, life is really a hot
mess on paper. … When you see it on paper, it’s real.

I’ve had cervical cancer twice so I don’t want to talk about
[cancer prevention] anymore.
I don’t have a big family history of it. ... We don’t have any
breast cancer or anything like that, so I’ve never really
worried too much about it.
Through the years, I skipped because my very first
[mammogram] hurt.
When I come in next week, I’ll talk to whoever my provider
is. … We can discuss it. We’ll see.
[PCP] just had asked if I was ready to quit, and I’m not
ready to do that.
I’m over the weight. Listen, I don’t care about that
anymore.
It seems like everyone that I’ve met that has gotten a
mammogram ends up with cancer. So that’s why I don’t
want to do it.
[PCP] just said that this was the first time it’s happened
here [the CDS being printed] and she wasn’t real familiar
with it either.

Note: Interviewees could be included under more than one subtheme.
CDS, clinical decision support; PCP, primary care provider.
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Table 4. CDS-Recommended Cancer Prevention and Screenings, Visit Discussions, and Decisions Made
Reported by Interviewees (n=37)
Cancer screening
or prevention
performed or
scheduled

n (%)

Type

n

Total
discussed at
visit, n (%)

Breast

13

10 (77%)

To be scheduled

4 (31%)

Cervical

14

9 (64%)

Pap performed
To be scheduled

5 (36%)
4 (29%)

Colorectal

15

13 (87%)

To be scheduled
Has FIT test at home

5 (38%)
1 (8%)

HPV

4

3 (75%)

Received vaccine

1 (25%)

Lung

12

1 (8%)

To be scheduled

1 (8%)

Reasons why no cancer screening or
prevention performed or scheduled

n (%)

Did not choose screening (undecided)
Deferred to next visit
Already scheduled prior to visit
Recent screen at different system
Did not state choice
Against screening
Did not choose screening (undecided)
Deferred to next visit
Pap scheduled prior
Recent screen at different system
Recent screen at different system
Did not choose screening (undecided)
Deferred to next visit
Against screening
Against vaccine
Did not choose vaccination (undecided)
Did not choose screening (undecided)
Deferred to next visit
Recent screen at different system

2 (15%)
2 (15%)
2 (15%)
1 (8%)
1 (8%)
1 (8%)
2 (14%)
1 (7%)
1 (7%)
1 (7%)
4 (27%)
3 (20%)
1 (7%)
1 (7%)
2 (50%)
1 (25%)
7 (58%)
3 (25%)
1 (8%)

Note: Participants could have more than one cancer screening and prevention need.
CDS, clinical decision support; FIT, fecal immunochemical test; HPV, human papillomavirus.

Some participants had already had the recommended
screening outside the health system, with the CDS acting
as a prompt for updating the electronic health record with
accurate information. Others simply did not decide on
cancer screening or prevention at the visit. Regarding use
of the CDS in decision-making, only 1 (13%) of the 8
participants who reported not reviewing the CDS with
their PCP also reported deciding to either schedule or
complete cancer prevention and screening items (data
not shown in Table 4). Conversely, 10 (59%) of the 17
participants who reported reviewing the CDS with their
PCP decided to be screened or take preventive measures.
It was unclear in the interviews if the remaining 12
respondents reviewed the CDS with their provider.

DISCUSSION

We conducted qualitative interviews with adults due
or overdue for cancer prevention and screening at
intervention primary care clinics participating in a
cluster-randomized controlled trial of personalized
CDS. Participants noted many strengths of the CDS
while providing opportunities for improvement. We
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found that the reported facilitators and barriers to cancer
prevention decision-making were primarily at the patient
level. While participants also noted multiple CDS-level
facilitators, the only CDS-level barrier was lack of some
PCPs using the CDS with patients. This may be a product
of the interview focus or could relate to PCP-perceived
time limitations.15,16,21,23
The personal importance of cancer prevention and
screening to patients seems to be a critical facilitator in
decision-making, likely the result of successful health
system and government prevention education efforts,
particularly for common screenings like mammography,
colonoscopy, and Pap tests. While many participants
reported making some sort of decision during their visit,
our findings suggest that knowledge on lung cancer
screening for those eligible may be lacking. Tools like the
CDS may help with this knowledge gap; however, PCP
buy-in and understanding of the risks and benefits of lowdose computed tomography scans are likely necessary for
patients and PCPs to make a shared decision regarding
lung cancer screening.43
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PCPs report not having enough time to go over decision
aids alongside patients.15 Yet, participants in this study
appeared to value the personalized recommendations
of the CDS in decision-making, including with PCPs,
findings supported by previous research that illustrated
the benefits of PCPs using decision aids with patients.17
Furthermore, our finding that most participants
wanted to discuss cancer screening and prevention
at their visit is consistent with previous research
showing overwhelming support for cancer screening.11
Concerns about PCP time limitations may be allayed by
recognizing how patients appreciate the CDS.19
PCPs may want to place higher weight on patient
preferences and needs when considering adopting
decision aids and CDS into practice. The participants
in this exploratory qualitative study appeared to be
influenced in their decision-making by PCPs who used
the CDS, with those who actually discussed the CDS
with their PCP reporting making more decisions about
cancer screening and prevention than those who did not.
This suggests the value of SDM between patient and PCP
with tools like the CDS as well as the influence that PCPs
have in aiding patients with decision-making,25,26 which
research such as our larger randomized controlled trial
can better assess.
PCPs may benefit from additional training in SDM and
patient engagement in order for CDS interventions to be
widely adopted into clinical practice.35 More responsibility
for using the CDS could also be moved to other team
members like medical assistants.44 Preimplementation,
qualitative interviews with key health system informants
showed that many saw CDS benefits for patients:
time savings, education, controlling health, reminders,
and exposure to cancer prevention and screening
recommendations.21
Limitations

This study did have limitations. Participants were
primarily White, female, and high school-educated (or
more) and were seen in a primary care clinic within a
single health system. Interviews also focused only on
patient perceptions. Future research could examine
the experiences of PCPs alongside patients using CDS
tools. In addition, our study did not explore PCP-level
barriers to cancer prevention and screening, as outside
of CDS use, these were not noted by participants. Other
research is available on PCP-level barriers to using
CDS.15,16,45 Furthermore, we only captured participants’
intentions, not whether they followed through with items
that could not be completed during their visit. However,
interviewing participants immediately following their
visit with their PCP limited recall bias.
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We could not determine from participant responses
to interview questions whether 12 patients reviewed
the CDS with their PCP or not. Our findings related
to decision-making and CDS use between patients
and PCPs are exploratory, as is the study outlined in
this paper. More research is needed on what actually
happens within clinic visits using CDS systems. We
also do not know how many patients were approached
by rooming staff to take part in the study or how many
declined. We did initially keep track of patients who
were eligible for the CDS due to having one or more
uncontrolled cardiovascular risk factors but did not
have any CDS areas related to cancer screening and
prevention. Instead, we trained the rooming staff to only
invite patients to participate if they were overdue for a
cancer screening and prevention item.
Lastly, the CDS system was available for all office visits,
not only for annual exams, where patient-presenting
problems were likely the focus of the visit rather than
cancer prevention and screening.

CONCLUSIONS

In individual interviews, adults due or overdue for breast,
cervical, colorectal, or lung cancer screening or HPV
vaccination described many benefits of an individually
tailored CDS tool, including around decision-making.
Use of the CDS with patients within a primary care visit
may positively assist shared decision-making, providing
experiential evidence of the value of CDS for both
patients and PCPs when making shared cancer prevention
and screening decisions.
Our qualitative findings highlight the importance of
getting information into patients’ hands, including
for facilitating SDM. The CDS appears to engage and
inform patients on cancer prevention and screening,
which may help them become more involved with their
own health care. Patients having personal access to
CDS may be particularly important, as we found some
participants reported their PCP did not utilize the CDS
with them.
Future research could examine whether patients prefer to
receive their CDS in advance of their PCP visit through
an online patient portal or during their visit. With the
nationwide adoption of virtual visits spurred by the
COVID-19 pandemic,46 CDS can be adapted for use in
electronic formats, such as within online patient portals.
Future research could examine the effectiveness of CDS
within virtual visits. CDS systems also have the potential
for greater scalability in primary care and beyond.

Original Research

Patient-Friendly Recap
• A clinical decision support (CDS) tool linked to the
electronic health record might help patients decide
whether or not to undergo recommended cancer
screening and prevention.
• Authors qualitatively analyzed interviews with 37
primary care patients to learn their perspectives
regarding point-of-care CDS content. While
areas for improving the tool were identified, some
participants reported it helped them make a
decision they otherwise would not have made.
• A personalized CDS tool for cancer screening and
prevention was found to be useful and a beneficial
addition to office visits. However, many primary
care providers did not use the tool with eligible
patients.
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